Published on 06/01/2026
Overcoming Challenges in Global Site Feasibility Assessments
Global site feasibility assessments are essential for selecting suitable clinical trial sites across diverse geographical regions. However, expanding feasibility efforts internationally introduces significant complexities. Sponsors and CROs must navigate regulatory differences, operational hurdles, and cultural nuances while ensuring consistent, quality-driven site selection. This tutorial explores the key challenges in global feasibility and how to mitigate them using standardized processes and informed strategies.
Why Global Feasibility Is More Complex Than Domestic
Unlike single-country feasibility efforts, global feasibility assessments must account for:
- Multiple regulatory environments
- Variations in site infrastructure and SOPs
- Different clinical practices and care standards
- Time zone and language barriers
- Diverse patient populations and recruitment timelines
These factors make data harmonization and feasibility comparisons more difficult, leading to increased trial start-up timelines and variability in study performance.
Major Challenges in Global Site Feasibility Assessments
1. Regulatory Variability Across Countries
- Every region has unique ethics and regulatory approval pathways
- Timelines and documentation requirements vary significantly
- For example, EMA timelines differ widely from CDSCO in India
2. Inconsistent Site Infrastructure and Resources
- Some regions may lack equipment, staff, or digital capabilities
- Site readiness varies by country and sponsor support systems
- Reliability of courier services and sample storage can also impact feasibility
3. Language and Cultural Barriers
- Feasibility forms may
4. Data Privacy and Protection Compliance
- GDPR (EU), HIPAA (USA), and country-specific laws impose different data handling rules
- Compliance requires adapting feasibility forms and data collection methods
- Feasibility systems must ensure encrypted and permissioned access
5. Limited Access to Historical Site Performance
- Global sites may lack a centralized registry for recruitment metrics
- Sponsors must rely on investigator self-reports or use third-party databases
- Site performance may be over- or under-stated without verification
Strategies to Overcome Global Feasibility Challenges
1. Use Standardized Feasibility Templates with Localization
Design standardized templates aligned with protocol needs, but allow localized versions to meet regulatory or language requirements. You can use formats from Pharma SOP templates and adjust based on region.
2. Implement Global CTMS and Dashboards
Use CTMS systems with region-specific fields and dashboards to track site-specific timelines, EC submissions, and investigator qualifications. Integration helps harmonize site comparison across countries.
3. Conduct Remote and On-Site Feasibility Checks
Leverage a hybrid approach of remote feasibility interviews and in-country monitoring visits. Include CRA input from regional teams familiar with local conditions.
4. Train Regional Teams in Feasibility SOPs
Conduct dedicated training for regional staff on global feasibility expectations, sponsor standards, and how to manage cultural sensitivities. Use checklists to ensure consistency across feasibility assessments.
5. Score Sites Using a Weighted, Data-Driven Model
- Assign scores to key feasibility criteria:
- Startup Timelines (30%)
- Infrastructure and Equipment (25%)
- Investigator and Team Experience (20%)
- Past Performance Data (15%)
- Compliance History (10%)
- Rank sites globally for strategic selection
Technology Enablers for Global Feasibility
- REDCap for multilingual feasibility data collection
- Global CTMS systems with EDC and eTMF integrations
- Feasibility tracker templates using Excel or Power BI
- AI-powered feasibility analysis tools
Several tools also offer compliance with regional data protection policies and can be reviewed via portals like StabilityStudies.in.
Documenting and Auditing Global Feasibility Efforts
As per USFDA and other regulators, site feasibility documentation must be audit-ready and preserved in the Trial Master File (TMF). Sponsors should ensure that feasibility outcomes are traceable and decisions justifiable.
Conclusion
Global site feasibility assessments present several operational and regulatory challenges. By standardizing processes, leveraging digital tools, and empowering regional teams, sponsors and CROs can overcome barriers and select sites that are not just eligible—but optimally equipped—for clinical trial success. A structured, transparent feasibility process ensures quality, speed, and global compliance.